Tempest Therapeutics CFO Resigns, Names Nicholas Rossettos as Replacement
TPST sits 31% above its 52-week low of $0.84.
Summary
Tempest Therapeutics disclosed that Justin Trojanowski will resign as Principal Financial Officer and Principal Accounting Officer effective September 1, with Nicholas Rossettos appointed as CFO and principal financial and accounting officer on the same date. The change follows a June 8-K that announced the resignation of the prior CFO and an internal replacement, suggesting continued turnover in the finance function. The company has been navigating severe cash constraints, reporting only $0.8 million in cash as of Q2 2026 and relying on warrant exercises and an equity line to fund operations. A CFO transition during a period of financial distress can raise concerns about stability, though the appointment of an internal successor may mitigate disruption. Investors will look for clarity on the reasons for the departure and any impact on the company's capital-raising efforts.
At the time of this announcement, TPST was trading at $1.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.6M. The 52-week trading range was $0.84 to $12.23. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.